Journey Medical Corporation (DERM)

Market Cap	127.64M
Revenue (ttm)	56.13M
Net Income (ttm)	-14.67M
Shares Out	20.89M
EPS (ttm)	-0.72
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	53,870
Open	5.71
Previous Close	5.92
Day's Range	5.71 - 6.11
52-Week Range	3.20 - 6.89
Beta	0.98
Analysts	Strong Buy
Price Target	10.00 (+63.67%)
Earnings Date	Mar 26, 2025

About DERM

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company’s marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topi...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Nov 12, 2021
• Employees: 41
• Stock Exchange: NASDAQ
• Ticker Symbol: DERM
• Website: https://journeymedicalcorp.com

Financial Performance

In 2024, Journey Medical's revenue was $56.13 million, a decrease of -29.11% compared to the previous year's $79.18 million. Losses were -$14.67 million, 280.8% more than in 2023.

Analyst Forecast

According to 2 analysts, the average rating for DERM stock is "Strong Buy." The 12-month stock price forecast is $10.0, which is an increase of 63.67% from the latest price.

Price Target

$10.0

(63.67% upside)

Analyst Consensus: Strong Buy